Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Department of Obstetrics and Gynecology, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Korea.
Yonsei Med J. 2023 Mar;64(3):204-212. doi: 10.3349/ymj.2022.0278.
The aims of this study were to evaluate the cumulative recurrence, reoperation, and pregnancy rates after ovarian endometrioma surgery at a single institution for more than a 5-year follow-up period.
This study was conducted as a retrospective chart review of patients with ovarian endometrioma who underwent surgery between January 2008 and March 2016. Study subjects included premenopausal women with at least 5 years of follow-up. Exclusion criteria were patients with stage I or II ovarian endometrioma, those who underwent hysterectomy or bilateral oophorectomy, and presence of residual ovarian lesions on the first postoperative ultrasonography at 3-6 months. Recurrence was defined as a cystic mass by ultrasonography.
A total of 756 patients were recruited. The median follow-up duration was 85.5 months (interquartile range, 71-107 months). Recurrent endometrioma was detected in 27.9% patients, and reoperation was performed in 8.3% patients. Cumulative rates at 24, 36, 60, and 120 months were 5.8%, 8.7%, 15.5% and 37.6%, respectively, for recurrence and 0.1%, 0.5%, 2.9%, and 15.1%, respectively, for reoperation. After multivariable analysis, age ≤31 years [hazard ratio (HR)=2.108; 95% confidence interval (CI)=1.522-2.921; <0.001], no subsequent pregnancy (HR=1.851; 95% CI=1.309-2.617; <0.001), and postoperative hormonal treatment ≤15 months (HR=2.869; 95% CI=2.088-3.941; <0.001) were significant risk factors for recurrent endometrioma. Among 315 patients who desired pregnancy, 54.0% were able to have a successful pregnancy and delivery.
Considering that longer postoperative hormonal treatment is the sole modifiable factor for recurrent endometrioma, we recommend long-term hormonal treatment until subsequent pregnancy, especially in younger women.
本研究旨在评估单中心超过 5 年的随访期间卵巢子宫内膜异位症手术后的累积复发、再次手术和妊娠率。
本研究为回顾性病历研究,纳入 2008 年 1 月至 2016 年 3 月期间接受卵巢子宫内膜异位症手术的患者。研究对象为至少随访 5 年的绝经前女性。排除标准为 I 期或 II 期卵巢子宫内膜异位症患者、接受子宫切除术或双侧卵巢切除术的患者以及术后 3-6 个月首次超声检查发现卵巢残留病变的患者。复发定义为超声检查发现囊性肿块。
共纳入 756 例患者。中位随访时间为 85.5 个月(四分位间距,71-107 个月)。27.9%的患者发现复发,8.3%的患者再次手术。24、36、60 和 120 个月时的累积复发率分别为 5.8%、8.7%、15.5%和 37.6%,再次手术率分别为 0.1%、0.5%、2.9%和 15.1%。多变量分析显示,年龄≤31 岁(风险比[HR]=2.108;95%置信区间[CI]=1.522-2.921;<0.001)、无后续妊娠(HR=1.851;95%CI=1.309-2.617;<0.001)和术后激素治疗≤15 个月(HR=2.869;95%CI=2.088-3.941;<0.001)是复发的显著危险因素。在 315 名有生育要求的患者中,54.0%能够成功妊娠和分娩。
考虑到术后激素治疗时间较长是唯一可改变的子宫内膜异位症复发因素,我们建议长期进行激素治疗直至后续妊娠,尤其是对于年轻女性。